Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods

Dikmen, Zeliha Gunnur; BAKIR, Nilay; YORGUN, HIKMET; KAYA, ERGUN BARIS; AYTEMIR, KUDRET; HAZIROLAN, TUNCAY; Çoteli, Cem; Canpolat, Ugur; Özer, Necla; ATES, AHMET HAKAN; ERDEMIR, AHMET GÜRKAN

doi:10.3906/sag-2103-194

Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods

Cem COTELİ, (Ankara Şehir Hastanesi, Kardiyoloji Bölümü, Ankara, Türkiye)

Tuncay HAZIROLAN, (Hacettepe Üniversitesi, Tıp Fakültesi, Radyoloji Anabilim Dalı, Ankara, Türkiye)

Kudret AYTEMİR, (Hacettepe Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Ahmet Gürkan ERDEMİR, (Hacettepe Üniversitesi, Tıp Fakültesi, Radyoloji Anabilim Dalı, Ankara, Türkiye)

Emine Nilay BAKIR, (Hacettepe Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, Ankara, Türkiye)

Uğur CANBOLAT, (Hacettepe Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Hikmet YORGUN, (Hacettepe Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Ahmet Hakan ATEŞ, (Hacettepe Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Ergün Barış KAYA, (Hacettepe Üniversitesi, Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Ankara, Türkiye)

Zeliha Günnur DİKMEN, (Hacettepe Üniversitesi, Tıp Fakültesi, Biyokimya Anabilim Dalı, Ankara, Türkiye)

Necla ÖZER, (Department of Cardiology, Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, Netherland)

Diğer Yazarlar

Turkish Journal of Medical Sciences

0 0

Yıl: 2022 Cilt: 52 Sayı: 1 Sayfa Aralığı: 175 - 187 Metin Dili: İngilizce DOI: 10.3906/sag-2103-194 İndeks Tarihi: 13-06-2022

Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods

Öz:

Background/aim: The presence of atrial fibrosis has already been known as a risk factor for atrial fibrillation (AF) development. We aimed to evaluate atrial fibrosis with previously defined three different methods, which were cardiac magnetic resonance imaging (C-MRI), echocardiographic strain imaging, and biomarkers and show the relationship between these methods in patients with AF scheduled for cryoballoon ablation. Materials and methods: A total of 30 patients were enrolled. Atrial T1 relaxation durations were measured using C-MRI before the procedure of atrial fibrillation catheter ablation. Fibroblast growth factor-21 (FGF-21) and fibroblast growth factor-23 (FGF-23) levels were measured at serum derived from the femoral artery (Peripheral FGF 21 and 23) and left atrium blood samples (Central FGF 21 and 23) before catheter ablation. Preprocedural transthoracic echocardiography was performed. The median follow-up duration for atrial tachyarrhythmia (ATa) recurrence was 13 (12–18 months) months. Results: The mean ages of the study group were 55.23 ± 12.37 years, and there were 17 (56.7%) female patients in study population. There were negative correlations between post contrast T1 relaxation durations of both posterior and posterosuperior atrium, and central FGF-23 (r: – 0.561; p = 0.003; r:–0.624; p = 0.001; Posterior T1 vs. central FGF-23 levels and Posterosuperior T1 vs central FGF-23 levels, respectively). The positive correlations were observed between postcontrast posterior T1 relaxation durations and left ventricle ejection fraction (r:0.671; p = 0.001); left atrial emptying fraction (r:0.482; p = 0.013); peak atrial longitudinal strain (r:0.605; p = 0.001), and peak atrial contraction strain (r:0.604; p = 0.001). Also negative correlation was observed between postcontrast posterior T1 relaxation durations, and left atrial volume index (r: – 0.467; p = 0.016). Conclusion: Our studies showed that there are correlations between T1 mapping of atrial tissue, biomarkers, and atrial mechanics evaluated with transthoracic echocardiography. Our findings are significant as they demonstrate the compatibility of these techniques for the atrial fibrosis evaluation.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Packer DL, Kowal RC, Wheelan KR, Irwin JM, Champagne J, Guerra PG et al. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. Journal of the American College of Cardiology 2013; 61 (16): 1713-1723. doi: 10.1016/j.jacc.2012.11.064
2. Calkins H, Hindricks G, Cappato R, Kim YH, Saad EB, Aguinaga L et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace 2018; 20 (1): e1-e160. doi: 10.1093/ europace/eux274
3. Darby AE. Recurrent Atrial Fibrillation After Catheter Ablation: Considerations for Repeat Ablation and Strategies to Optimize Success. Journal of Atrial Fibrillation 2016; 9 (1): 1427. doi: 10.4022/jafib.1427
4. Velagapudi P, Turagam MK, Leal MA, Kocheril AG. Atrial fibrosis: a risk stratifier for atrial fibrillation. Expert Review of Cardiovascular Therapy 2013; 11 (2): 155-160. doi: 10.1586/ erc.12.174
5. Canpolat U, Oto A, Hazirolan T, Sunman H, Yorgun H, Sahiner L et al. A prospective DE-MRI study evaluating the role of TGF-beta1 in left atrial fibrosis and implications for outcomes of cryoballoon-based catheter ablation: new insights into primary fibrotic atriocardiomyopathy. Journal of Cardiovascular Electrophysiology 2015; 26 (3): 251-259. doi: 10.1111/jce.12578
6. Qureshi NA, Kim SJ, Cantwell CD, Afonso VX, Bai W, Ali RL et al. Voltage during atrial fibrillation is superior to voltage during sinus rhythm in localizing areas of delayed enhancement on magnetic resonance imaging: An assessment of the posterior left atrium in patients with persistent atrial fibrillation. Heart Rhythm 2019; 16 (9): 1357-1367. doi: 10.1016/j.hrthm.2019.05.032
7. Kis Z, Hendriks AA, Muka T, Bramer WM, Kovacs I, SziliTorok T. The Role of Atrial Fibrosis Detected by Delayed - Enhancement MRI in Atrial Fibrillation Ablation. Current Medical Imaging Reviews 2020; 16 (2): 135-144. doi: 10.2174 /1573405614666180806130327
8. Reiter U, Reiter C, Krauter C, Fuchsjager M, Reiter G. Cardiac magnetic resonance T1 mapping. Part 2: Diagnostic potential and applications. European Journal of Radiology 2018; 109: 235-247. doi: 10.1016/j.ejrad.2018.10.013
9. Ling L-h, McLellan AJ, Taylor AJ, Iles LM, Ellims AH, Kumar S et al. Magnetic resonance post-contrast T1 mapping in the human atrium: validation and impact on clinical outcome after catheter ablation for atrial fibrillation. Heart Rhythm 2014; 11 (9): 1551-1559. doi: 10.1016/j.hrthm.2014.06.012
10. Sibley CT, Noureldin RA, Gai N, Nacif MS, Liu S, Turkbey EB et al. T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. Radiology 2012; 265 (3): 724-732. doi: 10.1148/radiol.12112721
11. Beinart R, Khurram IM, Liu S, Yarmohammadi H, Halperin HR, Bluemke DA et al. Cardiac magnetic resonance T1 mapping of left atrial myocardium. Heart Rhythm 2013; 10 (9): 1325-1331. doi: 10.1016/j.hrthm.2013.05.003
12. Mathew JS, Sachs MC, Katz R, Patton KK, Heckbert SR, Hoofnagle AN et al. Fibroblast growth factor-23 and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA) and the Cardiovascular Health Study (CHS). Circulation 2014; 130 (4): 298-307. doi: 10.1161/ circulationaha.113.005499
13. Han X, Chen C, Cheng G, Xie C, Yang M, Shou X et al. Serum fibroblast growth factor 21 levels are increased in atrial fibrillation patients. Cytokine 2015; 73(1): 176-180. doi: 10.1016/j.cyto.2015.02.019
14. Sugimoto T, Dulgheru R, Bernard A, Ilardi F, Contu L, Addetia K et al. Echocardiographic reference ranges for normal left ventricular 2D strain: results from the EACVI NORRE study. European Heart Journal - Cardiovascular Imaging 2017; 18 (8): 833-840. doi: 10.1093/ehjci/jex140
15. Canpolat U, Kocyigit D, Yalcin MU, Coteli C, Sener YZ, Oksul M et al. Long-term outcomes of pulmonary vein isolation using second-generation cryoballoon during atrial fibrillation ablation. Pacing and Clinical Electrophysiology 2019; 42 (7): 910-921. doi: 10.1111/pace.13721
16. Akoum N, Marrouche N. Assessment and impact of cardiac fibrosis on atrial fibrillation. Current Cardiology Reports 2014; 16 (8): 518. doi: 10.1007/s11886-014-0518-z
17. Jellis CL, Kwon DH. Myocardial T1 mapping: modalities and clinical applications. Cardiovascular Diagnosis and Therapy 2014; 4 (2): 126-137. doi: 10.3978/j.issn.2223-3652.2013.09.03
18. Sekiguchi H, Shimamoto K, Takano M, Kimura M, Takahashi Y, Tatsumi F et al. Cancer antigen-125 plasma level as a biomarker of new-onset atrial fibrillation in postmenopausal women. Heart 2017; 103 (17): 1368-1373. doi: 10.1136/ heartjnl-2016-310272
19. Apel A, Rachel P, Cohen O, Mayan H. Digoxin-associated decrease in parathyroid hormone (PTH) concentrations in patients with atrial fibrillation. European Journal of Clinical Investigation 2013; 43 (2): 152-158. doi: 10.1111/eci.12026
20. Wang R, Yi X, Li X, Jiang X. Fibroblast growth factor-21 is positively associated with atrial fibrosis in atrial fibrillation patients with rheumatic heart disease. International Journal of Clinical and Experimental 2015; 8 (11): 14901-14908
21. Wang F, Zhang SJ, Yao X, Tian DM, Zhang KQ, She DM et al. Circulating microRNA-1a is a biomarker of Graves’ disease patients with atrial fibrillation. Endocrine 2017; 57 (1): 125- 137. doi: 10.1007/s12020-017-1331-4
22. Szegedi I, Szapary L, Csecsei P, Csanadi Z, Csiba L. Potential Biological Markers of Atrial Fibrillation: A Chance to Prevent Cryptogenic Stroke. BioMed Research International 2017; 2017: 8153024. doi: 10.1155/2017/8153024
23. Hui TH, McClelland RL, Allison MA, Rodriguez CJ, Kronmal RA, Heckbert SR et al. The relationship of circulating fibroblast growth factor 21 levels with incident atrial fibrillation: The Multi-Ethnic Study of Atherosclerosis. Atherosclerosis 2018; 269: 86-91. doi: 10.1016/j.atherosclerosis.2017.12.026
24. Kestenbaum B, Sachs MC, Hoofnagle AN, Siscovick DS, Ix JH, Robinson-Cohen C et al. Fibroblast growth factor-23 and cardiovascular disease in the general population: the MultiEthnic Study of Atherosclerosis. Circulation: Heart Failure 2014; 7 (3): 409-417. doi: 10.1161/circheartfailure.113.000952
25. Li S, Zhu Z, Xue M, Yi X, Liang J, Niu C et al. Fibroblast growth factor 21 protects the heart from angiotensin II-induced cardiac hypertrophy and dysfunction via SIRT1. Biochimica et Biophysica Acta - Molecular Basis of Disease 2019; 1865 (6): 1241-1252. doi: 10.1016/j.bbadis.2019.01.019
26. Ferrer-Curriu G, Redondo-Angulo I, Guitart-Mampel M, Ruperez C, Mas-Stachurska A, Sitges M et al. Fibroblast growth factor-21 protects against fibrosis in hypertensive heart disease. The Journal of Pathology 2019; 248 (1): 30-40. doi: 10.1002/ path.5226
27. Refsgaard Holm M, Christensen H, Rasmussen J, Johansen ML, Schou M, Faber J et al. Fibroblast growth factor 21 in patients with cardiac cachexia: a possible role of chronic inflammation. ESC Heart Failure 2019; 6 (5): 983-991. doi: 10.1002/ehf2.12502
28. Feingold KR, Grunfeld C, Heuer JG, Gupta A, Cramer M, Zhang T et al. FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis. Endocrinology 2012; 153 (6): 2689-700. doi: 10.1210/en.2011- 1496
29. Durak BA, Karakan MS. Circulating Fibroblast Growth Factor-23 is Associated with Cardiovascular Prognosis and Graft Function in Renal Transplant Recipients. Cureus 2020; 12 (2): e7140. doi: 10.7759/cureus.7140
30. Kuga K, Kusakari Y, Uesugi K, Semba K, Urashima T, Akaike T et al. Fibrosis growth factor 23 is a promoting factor for cardiac fibrosis in the presence of transforming growth factor-β1. PloS One 2020; 15 (4): e0231905. doi: 10.1371/journal.pone.0231905
31. Begg GA, Karim R, Oesterlein T, Graham LN, Hogarth AJ, Page SP et al. Intra-cardiac and peripheral levels of biochemical markers of fibrosis in patients undergoing catheter ablation for atrial fibrillation. Europace 2017; 19 (12): 1944-1950. doi: 10.1093/europace/euw315
32. Begg GA, Karim R, Oesterlein T, Graham LN, Hogarth AJ, Page SP et al. Left atrial voltage, circulating biomarkers of fibrosis, and atrial fibrillation ablation. A prospective cohort study. PloS One 2018; 13 (1): e0189936. doi: 10.1371/journal. pone.0189936
33. Begg GA, Lip GY, Plein S, Tayebjee MH. Circulating biomarkers of fibrosis and cardioversion of atrial fibrillation: A prospective, controlled cohort study. Clinical Biochemistry 2017; 50 (1-2): 11-15. doi: 10.1016/j.clinbiochem.2016.09.008
34. Schaaf M, Andre P, Altman M, Maucort-Boulch D, Placide J, Chevalier P et al. Left atrial remodelling assessed by 2D and 3D echocardiography identifies paroxysmal atrial fibrillation. European Heart Journal - Cardiovascular Imaging 2017; 18 (1): 46-53. doi: 10.1093/ehjci/jew028
35. Im SI, Na JO, Kim SW, Choi CU, Kim JW, Yong HS et al. Adjusted left atrial emptying fraction as a predictor of procedural outcome after catheter ablation for atrial fibrillation. Texas Heart Institute Journal 2015; 42 (3): 216-225. doi: 10.14503/ thij-14-4524
36. Vieira MJ, Teixeira R, Goncalves L, Gersh BJ. Left atrial mechanics: echocardiographic assessment and clinical implications. Journal of the American Society of Echocardiography 2014; 27 (5): 463-478. doi: 10.1016/j. echo.2014.01.021
37. Motoki H, Negishi K, Kusunose K, Popovic ZB, Bhargava M, Wazni OM et al. Global left atrial strain in the prediction of sinus rhythm maintenance after catheter ablation for atrial fibrillation. Journal of the American Society of Echocardiography 2014; 27 (11): 1184-1192. doi: 10.1016/j. echo.2014.08.017
38. Spethmann S, Stuer K, Diaz I, Althoff T, Hewing B, Baumann G et al. Left atrial mechanics predict the success of pulmonary vein isolation in patients with atrial fibrillation. Journal of Interventional Cardiac Electrophysiology 2014; 40 (1): 53-62. doi: 10.1007/s10840-014-9876-0
39. Parwani AS, Morris DA, Blaschke F, Huemer M, Pieske B, Haverkamp W et al. Left atrial strain predicts recurrence of atrial arrhythmias after catheter ablation of persistent atrial fibrillation. Open Heart 2017; 4 (1): e000572. doi: 10.1136/ openhrt-2016-000572

APA	Çoteli C, HAZIROLAN T, AYTEMIR K, ERDEMIR A, BAKIR N, Canpolat U, YORGUN H, ATES A, KAYA E, Dikmen Z, Özer N (2022). Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods. , 175 - 187. 10.3906/sag-2103-194
Chicago	Çoteli Cem,HAZIROLAN TUNCAY,AYTEMIR KUDRET,ERDEMIR AHMET GÜRKAN,BAKIR Nilay,Canpolat Ugur,YORGUN HIKMET,ATES AHMET HAKAN,KAYA ERGUN BARIS,Dikmen Zeliha Gunnur,Özer Necla Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods. (2022): 175 - 187. 10.3906/sag-2103-194
MLA	Çoteli Cem,HAZIROLAN TUNCAY,AYTEMIR KUDRET,ERDEMIR AHMET GÜRKAN,BAKIR Nilay,Canpolat Ugur,YORGUN HIKMET,ATES AHMET HAKAN,KAYA ERGUN BARIS,Dikmen Zeliha Gunnur,Özer Necla Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods. , 2022, ss.175 - 187. 10.3906/sag-2103-194
AMA	Çoteli C,HAZIROLAN T,AYTEMIR K,ERDEMIR A,BAKIR N,Canpolat U,YORGUN H,ATES A,KAYA E,Dikmen Z,Özer N Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods. . 2022; 175 - 187. 10.3906/sag-2103-194
Vancouver	Çoteli C,HAZIROLAN T,AYTEMIR K,ERDEMIR A,BAKIR N,Canpolat U,YORGUN H,ATES A,KAYA E,Dikmen Z,Özer N Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods. . 2022; 175 - 187. 10.3906/sag-2103-194
IEEE	Çoteli C,HAZIROLAN T,AYTEMIR K,ERDEMIR A,BAKIR N,Canpolat U,YORGUN H,ATES A,KAYA E,Dikmen Z,Özer N "Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods." , ss.175 - 187, 2022. 10.3906/sag-2103-194
ISNAD	Çoteli, Cem vd. "Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods". (2022), 175-187. https://doi.org/10.3906/sag-2103-194

APA	Çoteli C, HAZIROLAN T, AYTEMIR K, ERDEMIR A, BAKIR N, Canpolat U, YORGUN H, ATES A, KAYA E, Dikmen Z, Özer N (2022). Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods. Turkish Journal of Medical Sciences, 52(1), 175 - 187. 10.3906/sag-2103-194
Chicago	Çoteli Cem,HAZIROLAN TUNCAY,AYTEMIR KUDRET,ERDEMIR AHMET GÜRKAN,BAKIR Nilay,Canpolat Ugur,YORGUN HIKMET,ATES AHMET HAKAN,KAYA ERGUN BARIS,Dikmen Zeliha Gunnur,Özer Necla Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods. Turkish Journal of Medical Sciences 52, no.1 (2022): 175 - 187. 10.3906/sag-2103-194
MLA	Çoteli Cem,HAZIROLAN TUNCAY,AYTEMIR KUDRET,ERDEMIR AHMET GÜRKAN,BAKIR Nilay,Canpolat Ugur,YORGUN HIKMET,ATES AHMET HAKAN,KAYA ERGUN BARIS,Dikmen Zeliha Gunnur,Özer Necla Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods. Turkish Journal of Medical Sciences, vol.52, no.1, 2022, ss.175 - 187. 10.3906/sag-2103-194
AMA	Çoteli C,HAZIROLAN T,AYTEMIR K,ERDEMIR A,BAKIR N,Canpolat U,YORGUN H,ATES A,KAYA E,Dikmen Z,Özer N Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods. Turkish Journal of Medical Sciences. 2022; 52(1): 175 - 187. 10.3906/sag-2103-194
Vancouver	Çoteli C,HAZIROLAN T,AYTEMIR K,ERDEMIR A,BAKIR N,Canpolat U,YORGUN H,ATES A,KAYA E,Dikmen Z,Özer N Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods. Turkish Journal of Medical Sciences. 2022; 52(1): 175 - 187. 10.3906/sag-2103-194
IEEE	Çoteli C,HAZIROLAN T,AYTEMIR K,ERDEMIR A,BAKIR N,Canpolat U,YORGUN H,ATES A,KAYA E,Dikmen Z,Özer N "Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods." Turkish Journal of Medical Sciences, 52, ss.175 - 187, 2022. 10.3906/sag-2103-194
ISNAD	Çoteli, Cem vd. "Evaluation of atrial fibrosis in atrial fibrillation patients with three different methods". Turkish Journal of Medical Sciences 52/1 (2022), 175-187. https://doi.org/10.3906/sag-2103-194